Hemin Inhibits NLRP3 Inflammasome Activation in Sepsis-induced Acute Lung Injury, Involving Heme Oxygenase-1
Overview
Pharmacology
Authors
Affiliations
NLRP3 inflammasome activation contributes to acute lung injury (ALI), accelerating caspase-1 maturation, and resulting in IL-1β and IL-18 over-production. Heme oxygenase-1 (HO-1) plays a protective role in ALI. This study investigated the effect of hemin (a potent HO-1 inducer) on NLRP3 inflammasome in sepsis-induced ALI. The sepsis model of cecal ligation and puncture (CLP) was used in C57BL6 mice. In vivo induction and suppression of HO-1 were performed by pretreatment with hemin and zinc protoporphyrin IX (ZnPP, a HO-1 competitive inhibitor) respectively. CLP triggered significant pulmonary damage, neutrophil infiltration, increased levels of IL-1β and IL-18, and edema formation in the lung. Hemin pretreatment exerted inhibitory effect on lung injury and attenuated IL-1β and IL-18 secretion in serum and lung tissue. In lung tissues, hemin down-regulated mRNA and protein levels of NLRP3, ASC and caspase-1. Moreover, hemin reduced malondialdehyde and reactive oxygen species production, and inhibited NF-κB and NLRP3 inflammasome activity. Meanwhile, hemin significantly increased HO-1 mRNA and protein expression and HO-1 enzymatic activity. In contrast, no significant differences were observed between the CLP and ZnPP groups. Our study suggests that hemin-inhibited NLRP3 inflammasome activation involved HO-1, reducing IL-1β and IL-18 secretion and limiting the inflammatory response.
Martin-Loro F, Cano-Cano F, Ortega M, Cuevas B, Gomez-Jaramillo L, Gonzalez-Montelongo M Int J Mol Sci. 2024; 25(15).
PMID: 39126007 PMC: 11313200. DOI: 10.3390/ijms25158440.
Wang R, Wang Y, Liu H, Zhu J, Fang C, Xu W Chin Med. 2024; 19(1):40.
PMID: 38433216 PMC: 10910709. DOI: 10.1186/s13020-024-00897-y.
Sepsis in elderly patients: the role of neutrophils in pathophysiology and therapy.
Ramoni D, Tirandi A, Montecucco F, Liberale L Intern Emerg Med. 2024; 19(4):901-917.
PMID: 38294676 PMC: 11186952. DOI: 10.1007/s11739-023-03515-1.
Khoshnavay Foumani M, Amirshahrokhi K, Namjoo Z, Niapour A Naunyn Schmiedebergs Arch Pharmacol. 2023; 397(7):4727-4736.
PMID: 38133658 DOI: 10.1007/s00210-023-02914-7.
Chen J, Zhou L, Li X, Wu X, Li Y, Si L Naunyn Schmiedebergs Arch Pharmacol. 2023; 397(4):2241-2255.
PMID: 37812239 DOI: 10.1007/s00210-023-02706-z.